Biocon Buoyant On ‘Unique Positioning’ Of Partnered COVID-19 Antibody
Executive Summary
Biocon management signals the potential of its partnered entry with Serum Institute and Adagio Therapeutics into the communicable diseases segment. Continuing large supply opportunities for COVID-19 vaccines and prospects for boosters, alongside the promising profile of the neutralizing antibody being developed by its US-based partner, also bode well.
You may also be interested in...
Biocon-Viatris Biosimilars Combine: Deal Or No Deal?
Are Viatris and long-standing partner Biocon mulling a consolidation of their biosimilars business? Some analysts suggest any deal that positions Viatris as a minority stakeholder in a potential combine doesn’t bode well for the US firm.
Coronavirus Notebook: EMA Begins Assessing AZ’s Evusheld, Apeiron Starts Phase I Trial Of Inhaled APN01
The UK has explained its strategy for administering COVID-19 vaccines to people who have been partially immunized abroad.
Coronavirus Update: Japan Approves Sotrovimab
Japan approves a second antibody therapy for COVID-19 in short order, while India gives the go-ahead to a local clinical program for Novavax/Serum Institute's recombinant protein vaccine candidate.